Presented at new research sessions at the 36th annual meeting of the American College of Neuropsychopharmacology, December 8–12, 1997; the 151st annual meeting of the American Psychiatric Association, May 30–June 4, 1998; and the 53rd annual meeting of the Society of Biological Psychiatry, May 27–30, 1998. Received May 27, 1998; revision received Jan. 19, 1999; accepted Jan. 26, 1999. From the Clinical Neuroscience Division, Laboratory of Neuroscience, Harvard Medical School Consolidated Department of Psychiatry at Brockton/West Roxbury Veterans Affairs Medical Center; and the Surgical Planning Laboratory, Magnetic Resonance Imaging Division, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston. Address reprint requests to Drs. McCarley and Shenton, Department of Psychiatry, Harvard Medical School/Brockton VA Medical Center, Psychiatry (116A), 940 Belmont St., Brockton, MA 02301; email@example.com or firstname.lastname@example.org (e-mail). Supported by NIMH grants MH-01110 and MH-50747 (Dr. Shenton) and MH-40799 (Dr. McCarley), by awards from the Department of Veterans Affairs Medical Research Service and the Brockton VA Center for Clinical and Basic Neuroscience Studies of Schizophrenia (Dr. McCarley), by the Commonwealth of Massachusetts Research Center (Dr. McCarley), by NIH/NCRR grant RR-13218 (Dr. Jolesz), and by NSF grant RR-11747 (Dr. Kikinis). The authors thank Joanna Gainski, B.S., K. Claire Stylianopoulos, B.A., and Marie Fairbanks for technical and administrative assistance.